UniQure stock crashes over 50% today after FDA says Huntington’s therapy data isn’t enough - here's what investors need to know

QURE stock price today: UniQure's stock crashed Monday after the FDA declared data for its Huntington's disease gene therapy, AMT-130, insufficient for approval. This unexpected FDA decision surprised investors and the company. Earlier, promising trial results had boosted UniQure shares significantly. The company is now seeking to engage with regulators to find a path forward for the therapy.